CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.
Acta obstetricia et gynecologica Scandinavica（2020）
摘要
Reduction of CA-125 levels during neoadjuvant chemotherapy provides an early predictive tool that strongly correlates with successful cytoreductive surgery and long-term clinical outcome in patients with advanced high grade serous and endometrioid ovarian cancer.
更多查看译文
关键词
CA-125,advanced ovarian cancer,neoadjuvant chemotherapy,primary debulking surgery
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要